Neste vídeo, Dr. Carlos Rieder, médico neurologista, presidente da Academia Brasileira de Neurologia e professor de Neurologia da Universidade Federal Ciências da Saúde de Porto Alegre (UFCSPA), comenta sobre alguns trabalhos que foram apresentados na Reunião Anual do AAN 2022, a respeito dos distúrbios do movimento - com enfoque em doença de Parkinson.
Reunião Anual do AAN: Biomarcadores e manejo dos distúrbios do movimento
Escrito por: Zilda Machado Meneghelo em 3 de maio de 2022
1 min de leitura
Referências
Daniel Weintraub et al., Pimavanserin treatment of hallucinations and delusions in patients with Parkinson’s disease dementia: post hoc analysis of the HARMONY trial. Presented at 2022 AAN Annual Meeting.
Vincent Chang et al., Effect of LRRK2 and GBA Mutations on Parkinson’s Disease Clinical Progression in Elderly Patients. Presented at 2022 AAN Annual Meeting.
Alexander Mihaescu et al., Amyloid beta deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort. Parkinson’s Progression Marker Initiative (PPMI) cohort. Presented at 2022 AAN Annual Meeting.
Bernard M. Ravina, MD, MSCE et al., PRAX-944-221: A Phase 2 Clinical Trial Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Adults with Essential Tremor. Presented at 2022 AAN Annual Meeting.
